Global Hemophilia Gene Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Hemophilia Gene Therapy market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.

The Global Info Research report includes an overview of the development of the Hemophilia Gene Therapy industry chain, the market status of Hemophilia A Gene Therapy (Hemophilia A, Hemophilia B), Hemophilia B Gene Therapy (Hemophilia A, Hemophilia B), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Hemophilia Gene Therapy.

Regionally, the report analyzes the Hemophilia Gene Therapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Hemophilia Gene Therapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Hemophilia Gene Therapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Hemophilia Gene Therapy industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Hemophilia A, Hemophilia B).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Hemophilia Gene Therapy market.

Regional Analysis: The report involves examining the Hemophilia Gene Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Hemophilia Gene Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Hemophilia Gene Therapy:
Company Analysis: Report covers individual Hemophilia Gene Therapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Hemophilia Gene Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hemophilia A Gene Therapy, Hemophilia B Gene Therapy).

Technology Analysis: Report covers specific technologies relevant to Hemophilia Gene Therapy. It assesses the current state, advancements, and potential future developments in Hemophilia Gene Therapy areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Hemophilia Gene Therapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Hemophilia Gene Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
    Hemophilia A
    Hemophilia B

Market segment by Application
    Hemophilia A Gene Therapy
    Hemophilia B Gene Therapy

Market segment by players, this report covers
    Spark Therapeutics
    Ultragenyx
    Shire PLC
    Sangamo Therapeutics
    Bioverativ
    BioMarin
    uniQure
    Freeline Therapeutics

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Hemophilia Gene Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Hemophilia Gene Therapy, with revenue, gross margin and global market share of Hemophilia Gene Therapy from 2019 to 2024.
Chapter 3, the Hemophilia Gene Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Hemophilia Gene Therapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Hemophilia Gene Therapy.
Chapter 13, to describe Hemophilia Gene Therapy research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Hemophilia Gene Therapy
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Hemophilia Gene Therapy by Type
        1.3.1 Overview: Global Hemophilia Gene Therapy Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Hemophilia Gene Therapy Consumption Value Market Share by Type in 2023
        1.3.3 Hemophilia A
        1.3.4 Hemophilia B
    1.4 Global Hemophilia Gene Therapy Market by Application
        1.4.1 Overview: Global Hemophilia Gene Therapy Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hemophilia A Gene Therapy
        1.4.3 Hemophilia B Gene Therapy
    1.5 Global Hemophilia Gene Therapy Market Size & Forecast
    1.6 Global Hemophilia Gene Therapy Market Size and Forecast by Region
        1.6.1 Global Hemophilia Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Hemophilia Gene Therapy Market Size by Region, (2019-2030)
        1.6.3 North America Hemophilia Gene Therapy Market Size and Prospect (2019-2030)
        1.6.4 Europe Hemophilia Gene Therapy Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Hemophilia Gene Therapy Market Size and Prospect (2019-2030)
        1.6.6 South America Hemophilia Gene Therapy Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Hemophilia Gene Therapy Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Spark Therapeutics
        2.1.1 Spark Therapeutics Details
        2.1.2 Spark Therapeutics Major Business
        2.1.3 Spark Therapeutics Hemophilia Gene Therapy Product and Solutions
        2.1.4 Spark Therapeutics Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Spark Therapeutics Recent Developments and Future Plans
    2.2 Ultragenyx
        2.2.1 Ultragenyx Details
        2.2.2 Ultragenyx Major Business
        2.2.3 Ultragenyx Hemophilia Gene Therapy Product and Solutions
        2.2.4 Ultragenyx Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Ultragenyx Recent Developments and Future Plans
    2.3 Shire PLC
        2.3.1 Shire PLC Details
        2.3.2 Shire PLC Major Business
        2.3.3 Shire PLC Hemophilia Gene Therapy Product and Solutions
        2.3.4 Shire PLC Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Shire PLC Recent Developments and Future Plans
    2.4 Sangamo Therapeutics
        2.4.1 Sangamo Therapeutics Details
        2.4.2 Sangamo Therapeutics Major Business
        2.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Product and Solutions
        2.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Sangamo Therapeutics Recent Developments and Future Plans
    2.5 Bioverativ
        2.5.1 Bioverativ Details
        2.5.2 Bioverativ Major Business
        2.5.3 Bioverativ Hemophilia Gene Therapy Product and Solutions
        2.5.4 Bioverativ Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Bioverativ Recent Developments and Future Plans
    2.6 BioMarin
        2.6.1 BioMarin Details
        2.6.2 BioMarin Major Business
        2.6.3 BioMarin Hemophilia Gene Therapy Product and Solutions
        2.6.4 BioMarin Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 BioMarin Recent Developments and Future Plans
    2.7 uniQure
        2.7.1 uniQure Details
        2.7.2 uniQure Major Business
        2.7.3 uniQure Hemophilia Gene Therapy Product and Solutions
        2.7.4 uniQure Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 uniQure Recent Developments and Future Plans
    2.8 Freeline Therapeutics
        2.8.1 Freeline Therapeutics Details
        2.8.2 Freeline Therapeutics Major Business
        2.8.3 Freeline Therapeutics Hemophilia Gene Therapy Product and Solutions
        2.8.4 Freeline Therapeutics Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Freeline Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Hemophilia Gene Therapy Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Hemophilia Gene Therapy by Company Revenue
        3.2.2 Top 3 Hemophilia Gene Therapy Players Market Share in 2023
        3.2.3 Top 6 Hemophilia Gene Therapy Players Market Share in 2023
    3.3 Hemophilia Gene Therapy Market: Overall Company Footprint Analysis
        3.3.1 Hemophilia Gene Therapy Market: Region Footprint
        3.3.2 Hemophilia Gene Therapy Market: Company Product Type Footprint
        3.3.3 Hemophilia Gene Therapy Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Hemophilia Gene Therapy Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Hemophilia Gene Therapy Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Hemophilia Gene Therapy Consumption Value Market Share by Application (2019-2024)
    5.2 Global Hemophilia Gene Therapy Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Hemophilia Gene Therapy Consumption Value by Type (2019-2030)
    6.2 North America Hemophilia Gene Therapy Consumption Value by Application (2019-2030)
    6.3 North America Hemophilia Gene Therapy Market Size by Country
        6.3.1 North America Hemophilia Gene Therapy Consumption Value by Country (2019-2030)
        6.3.2 United States Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        6.3.3 Canada Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        6.3.4 Mexico Hemophilia Gene Therapy Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Hemophilia Gene Therapy Consumption Value by Type (2019-2030)
    7.2 Europe Hemophilia Gene Therapy Consumption Value by Application (2019-2030)
    7.3 Europe Hemophilia Gene Therapy Market Size by Country
        7.3.1 Europe Hemophilia Gene Therapy Consumption Value by Country (2019-2030)
        7.3.2 Germany Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        7.3.3 France Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        7.3.5 Russia Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        7.3.6 Italy Hemophilia Gene Therapy Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Hemophilia Gene Therapy Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Hemophilia Gene Therapy Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Region
        8.3.1 Asia-Pacific Hemophilia Gene Therapy Consumption Value by Region (2019-2030)
        8.3.2 China Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        8.3.3 Japan Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        8.3.4 South Korea Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        8.3.5 India Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        8.3.7 Australia Hemophilia Gene Therapy Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Hemophilia Gene Therapy Consumption Value by Type (2019-2030)
    9.2 South America Hemophilia Gene Therapy Consumption Value by Application (2019-2030)
    9.3 South America Hemophilia Gene Therapy Market Size by Country
        9.3.1 South America Hemophilia Gene Therapy Consumption Value by Country (2019-2030)
        9.3.2 Brazil Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        9.3.3 Argentina Hemophilia Gene Therapy Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Hemophilia Gene Therapy Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Hemophilia Gene Therapy Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Country
        10.3.1 Middle East & Africa Hemophilia Gene Therapy Consumption Value by Country (2019-2030)
        10.3.2 Turkey Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Hemophilia Gene Therapy Market Size and Forecast (2019-2030)
        10.3.4 UAE Hemophilia Gene Therapy Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Hemophilia Gene Therapy Market Drivers
    11.2 Hemophilia Gene Therapy Market Restraints
    11.3 Hemophilia Gene Therapy Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Hemophilia Gene Therapy Industry Chain
    12.2 Hemophilia Gene Therapy Upstream Analysis
    12.3 Hemophilia Gene Therapy Midstream Analysis
    12.4 Hemophilia Gene Therapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Hemophilia Gene Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Hemophilia Gene Therapy Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Hemophilia Gene Therapy Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Hemophilia Gene Therapy Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Spark Therapeutics Company Information, Head Office, and Major Competitors
    Table 6. Spark Therapeutics Major Business
    Table 7. Spark Therapeutics Hemophilia Gene Therapy Product and Solutions
    Table 8. Spark Therapeutics Hemophilia Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Spark Therapeutics Recent Developments and Future Plans
    Table 10. Ultragenyx Company Information, Head Office, and Major Competitors
    Table 11. Ultragenyx Major Business
    Table 12. Ultragenyx Hemophilia Gene Therapy Product and Solutions
    Table 13. Ultragenyx Hemophilia Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Ultragenyx Recent Developments and Future Plans
    Table 15. Shire PLC Company Information, Head Office, and Major Competitors
    Table 16. Shire PLC Major Business
    Table 17. Shire PLC Hemophilia Gene Therapy Product and Solutions
    Table 18. Shire PLC Hemophilia Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Shire PLC Recent Developments and Future Plans
    Table 20. Sangamo Therapeutics Company Information, Head Office, and Major Competitors
    Table 21. Sangamo Therapeutics Major Business
    Table 22. Sangamo Therapeutics Hemophilia Gene Therapy Product and Solutions
    Table 23. Sangamo Therapeutics Hemophilia Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Sangamo Therapeutics Recent Developments and Future Plans
    Table 25. Bioverativ Company Information, Head Office, and Major Competitors
    Table 26. Bioverativ Major Business
    Table 27. Bioverativ Hemophilia Gene Therapy Product and Solutions
    Table 28. Bioverativ Hemophilia Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Bioverativ Recent Developments and Future Plans
    Table 30. BioMarin Company Information, Head Office, and Major Competitors
    Table 31. BioMarin Major Business
    Table 32. BioMarin Hemophilia Gene Therapy Product and Solutions
    Table 33. BioMarin Hemophilia Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. BioMarin Recent Developments and Future Plans
    Table 35. uniQure Company Information, Head Office, and Major Competitors
    Table 36. uniQure Major Business
    Table 37. uniQure Hemophilia Gene Therapy Product and Solutions
    Table 38. uniQure Hemophilia Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. uniQure Recent Developments and Future Plans
    Table 40. Freeline Therapeutics Company Information, Head Office, and Major Competitors
    Table 41. Freeline Therapeutics Major Business
    Table 42. Freeline Therapeutics Hemophilia Gene Therapy Product and Solutions
    Table 43. Freeline Therapeutics Hemophilia Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Freeline Therapeutics Recent Developments and Future Plans
    Table 45. Global Hemophilia Gene Therapy Revenue (USD Million) by Players (2019-2024)
    Table 46. Global Hemophilia Gene Therapy Revenue Share by Players (2019-2024)
    Table 47. Breakdown of Hemophilia Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 48. Market Position of Players in Hemophilia Gene Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 49. Head Office of Key Hemophilia Gene Therapy Players
    Table 50. Hemophilia Gene Therapy Market: Company Product Type Footprint
    Table 51. Hemophilia Gene Therapy Market: Company Product Application Footprint
    Table 52. Hemophilia Gene Therapy New Market Entrants and Barriers to Market Entry
    Table 53. Hemophilia Gene Therapy Mergers, Acquisition, Agreements, and Collaborations
    Table 54. Global Hemophilia Gene Therapy Consumption Value (USD Million) by Type (2019-2024)
    Table 55. Global Hemophilia Gene Therapy Consumption Value Share by Type (2019-2024)
    Table 56. Global Hemophilia Gene Therapy Consumption Value Forecast by Type (2025-2030)
    Table 57. Global Hemophilia Gene Therapy Consumption Value by Application (2019-2024)
    Table 58. Global Hemophilia Gene Therapy Consumption Value Forecast by Application (2025-2030)
    Table 59. North America Hemophilia Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 60. North America Hemophilia Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 61. North America Hemophilia Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 62. North America Hemophilia Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 63. North America Hemophilia Gene Therapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 64. North America Hemophilia Gene Therapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 65. Europe Hemophilia Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 66. Europe Hemophilia Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 67. Europe Hemophilia Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 68. Europe Hemophilia Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 69. Europe Hemophilia Gene Therapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 70. Europe Hemophilia Gene Therapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 71. Asia-Pacific Hemophilia Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 72. Asia-Pacific Hemophilia Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 73. Asia-Pacific Hemophilia Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 74. Asia-Pacific Hemophilia Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 75. Asia-Pacific Hemophilia Gene Therapy Consumption Value by Region (2019-2024) & (USD Million)
    Table 76. Asia-Pacific Hemophilia Gene Therapy Consumption Value by Region (2025-2030) & (USD Million)
    Table 77. South America Hemophilia Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 78. South America Hemophilia Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 79. South America Hemophilia Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 80. South America Hemophilia Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 81. South America Hemophilia Gene Therapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 82. South America Hemophilia Gene Therapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 83. Middle East & Africa Hemophilia Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
    Table 84. Middle East & Africa Hemophilia Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
    Table 85. Middle East & Africa Hemophilia Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
    Table 86. Middle East & Africa Hemophilia Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
    Table 87. Middle East & Africa Hemophilia Gene Therapy Consumption Value by Country (2019-2024) & (USD Million)
    Table 88. Middle East & Africa Hemophilia Gene Therapy Consumption Value by Country (2025-2030) & (USD Million)
    Table 89. Hemophilia Gene Therapy Raw Material
    Table 90. Key Suppliers of Hemophilia Gene Therapy Raw Materials
List of Figures
    Figure 1. Hemophilia Gene Therapy Picture
    Figure 2. Global Hemophilia Gene Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Hemophilia Gene Therapy Consumption Value Market Share by Type in 2023
    Figure 4. Hemophilia A
    Figure 5. Hemophilia B
    Figure 6. Global Hemophilia Gene Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 7. Hemophilia Gene Therapy Consumption Value Market Share by Application in 2023
    Figure 8. Hemophilia A Gene Therapy Picture
    Figure 9. Hemophilia B Gene Therapy Picture
    Figure 10. Global Hemophilia Gene Therapy Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 11. Global Hemophilia Gene Therapy Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 12. Global Market Hemophilia Gene Therapy Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 13. Global Hemophilia Gene Therapy Consumption Value Market Share by Region (2019-2030)
    Figure 14. Global Hemophilia Gene Therapy Consumption Value Market Share by Region in 2023
    Figure 15. North America Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 16. Europe Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 17. Asia-Pacific Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 18. South America Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 19. Middle East and Africa Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 20. Global Hemophilia Gene Therapy Revenue Share by Players in 2023
    Figure 21. Hemophilia Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 22. Global Top 3 Players Hemophilia Gene Therapy Market Share in 2023
    Figure 23. Global Top 6 Players Hemophilia Gene Therapy Market Share in 2023
    Figure 24. Global Hemophilia Gene Therapy Consumption Value Share by Type (2019-2024)
    Figure 25. Global Hemophilia Gene Therapy Market Share Forecast by Type (2025-2030)
    Figure 26. Global Hemophilia Gene Therapy Consumption Value Share by Application (2019-2024)
    Figure 27. Global Hemophilia Gene Therapy Market Share Forecast by Application (2025-2030)
    Figure 28. North America Hemophilia Gene Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 29. North America Hemophilia Gene Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 30. North America Hemophilia Gene Therapy Consumption Value Market Share by Country (2019-2030)
    Figure 31. United States Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 32. Canada Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 33. Mexico Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 34. Europe Hemophilia Gene Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 35. Europe Hemophilia Gene Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 36. Europe Hemophilia Gene Therapy Consumption Value Market Share by Country (2019-2030)
    Figure 37. Germany Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 38. France Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 39. United Kingdom Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 40. Russia Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 41. Italy Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 42. Asia-Pacific Hemophilia Gene Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 43. Asia-Pacific Hemophilia Gene Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 44. Asia-Pacific Hemophilia Gene Therapy Consumption Value Market Share by Region (2019-2030)
    Figure 45. China Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 46. Japan Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 47. South Korea Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 48. India Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 49. Southeast Asia Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 50. Australia Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 51. South America Hemophilia Gene Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 52. South America Hemophilia Gene Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 53. South America Hemophilia Gene Therapy Consumption Value Market Share by Country (2019-2030)
    Figure 54. Brazil Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 55. Argentina Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 56. Middle East and Africa Hemophilia Gene Therapy Consumption Value Market Share by Type (2019-2030)
    Figure 57. Middle East and Africa Hemophilia Gene Therapy Consumption Value Market Share by Application (2019-2030)
    Figure 58. Middle East and Africa Hemophilia Gene Therapy Consumption Value Market Share by Country (2019-2030)
    Figure 59. Turkey Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 60. Saudi Arabia Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 61. UAE Hemophilia Gene Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 62. Hemophilia Gene Therapy Market Drivers
    Figure 63. Hemophilia Gene Therapy Market Restraints
    Figure 64. Hemophilia Gene Therapy Market Trends
    Figure 65. Porters Five Forces Analysis
    Figure 66. Manufacturing Cost Structure Analysis of Hemophilia Gene Therapy in 2023
    Figure 67. Manufacturing Process Analysis of Hemophilia Gene Therapy
    Figure 68. Hemophilia Gene Therapy Industrial Chain
    Figure 69. Methodology
    Figure 70. Research Process and Data Source

Companies Mentioned

Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics